Matthew Aussprung
Rheumatology · Spartanburg, SCNPI 1396109286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 357 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Johnson & Johnson$962
- AbbVie$894
- GSK$801
- Novartis$495
- Mallinckrodt Hospital Products Inc.$328
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,60997%
- Education$2123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 105 | $1,443 |
| Johnson & Johnson | 55 | $962 |
| AbbVie | 44 | $894 |
| GSK | 22 | $801 |
| Novartis | 23 | $495 |
| Mallinckrodt Hospital Products Inc. | 12 | $328 |
| Pfizer | 17 | $306 |
| UCB, Inc. | 17 | $259 |
| AstraZeneca(2 entities) | 11 | $240 |
| Lilly USA, LLC | 13 | $228 |
| ANI Pharmaceuticals, Inc. | 8 | $149 |
| Actelion Pharmaceuticals US, Inc. | 3 | $119 |
| Boehringer Ingelheim | 5 | $111 |
| Organon | 3 | $79 |
| Aurinia Pharma U.S., Inc. | 4 | $63 |
| Octapharma USA, Inc. | 1 | $58 |
| Scilex Pharmaceuticals Inc. | 2 | $46 |
| Genentech USA, Inc. | 3 | $45 |
| Sanofi | 2 | $39 |
| Radius Health, Inc. | 1 | $31 |
| Bristol Myers Squibb | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Sandoz | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$245
- SIMPONI ARIA$134
- Tremfya$134
- EVENITY$123
- Otezla$102
How this compares
$6,821 in reported general payments places this provider in the 60th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 140 | $865,976 |
| Humira(Cf) PenAdalimumab | 103 | $698,287 |
| Enbrel SureclickEtanercept | 38 | $287,466 |
| Taltz AutoinjectorIxekizumab | 37 | $282,225 |
| Orencia ClickjectAbatacept | 50 | $273,499 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $258,859 |
| Xeljanz XrTofacitinib Citrate | 30 | $164,237 |
| KevzaraSarilumab | 36 | $146,996 |
| NucalaMepolizumab | 13 | $135,236 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $124,904 |
| SimponiGolimumab | 15 | $92,001 |
| OrenciaAbatacept | 15 | $84,591 |
| Enbrel MiniEtanercept | 11 | $76,952 |
| BenlystaBelimumab | 14 | $63,727 |
| XeljanzTofacitinib Citrate | 13 | $48,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $894 | $865,976140 claims |
| GSKNucala, Benlysta | $801 | $198,96427 claims |
| SanofiKevzara | $39 | $146,99636 claims |
| Johnson & JohnsonSimponi | $962 | $92,00115 claims |
| PfizerXeljanz | $306 | $48,77213 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $46 | $1,21720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Spartanburg
- Margaret CurranSpartanburg$9K
- Sunita DiaSpartanburg$5K
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.